Lonza Tampa to Import Psychedelic Shrooms for Science
Published Date: 2/18/2025
Notice
Summary
Lonza Tampa, LLC wants to become an official importer of psilocybin, a controlled substance. This means they’ll be allowed to bring this drug into the U.S. for research or medical use. People who make or use these drugs can share their thoughts or ask for a hearing by March 20, 2025.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Approval Would Allow Psilocybin Imports for Research
Lonza Tampa, LLC applied on February 4, 2025 to be registered to import psilocybin (drug code 7437, Schedule I) as bulk active pharmaceutical ingredient and as finished dosage units for clinical trials, research, and analytical purposes. If approved, that registration would authorize Lonza Tampa to import those kinds of psilocybin shipments for research use. Stakeholders may submit comments or request a hearing by March 20, 2025.
Commercial Import of Finished Psilocybin Not Authorized
The notice states that authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms of psilocybin for commercial sale. That means this registration, if issued, would not permit importing finished psilocybin products for commercial retail or distribution.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-02733, Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become a big-time maker of marijuana and related substances for research and clinical trials. If you’re a current manufacturer or interested party, you can share your thoughts or ask for a hearing by April 21, 2025. This move helps boost scientific studies but doesn’t change any other drug activities or costs right now.
Next: 2025-02738, Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to become a big-time maker of special research drugs called psilocybin and psilocyn. They plan to import these substances to help with science and medicine, not to sell or distribute them. If you have thoughts or want a hearing, you’ve got until April 21, 2025, to speak up!